Cargando…
CBP/Catenin Antagonist Safely Eliminates Drug Resistant Leukemia Initiating Cells
CBP and p300 are highly homologous transcriptional coactivators with unique, non-redundant roles that bind a wide array of proteins, including catenins – β and γ. ICG-001 is a small molecule inhibitor that specifically inhibits the CBP/catenin interaction. Importantly, ICG-001 does not inhibit the p...
Autores principales: | Zhao, Yi, Masiello, David, McMillian, Michael, Nguyen, Cu, Wu, Yongfeng, Melendez, Elizabeth, Smbatyan, Goar, Kida, Aiko, He, Yumin, Teo, Jia-Ling, Kahn, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526055/ https://www.ncbi.nlm.nih.gov/pubmed/26657156 http://dx.doi.org/10.1038/onc.2015.438 |
Ejemplares similares
-
CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer
por: Ring, Alexander, et al.
Publicado: (2018) -
Small molecule p300/catenin antagonist enhances hematopoietic recovery after radiation
por: Zhao, Yi, et al.
Publicado: (2017) -
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
por: Manegold, Philipp, et al.
Publicado: (2018) -
Small molecule inhibition of CBP/catenin interactions eliminates drug resistant clones in acute lymphoblastic leukemia
por: Gang, Eun Ji, et al.
Publicado: (2013) -
The Mode of Stem Cell Division Is Dependent on the Differential Interaction of β-Catenin with the Kat3 Coactivators CBP or p300
por: Lukaszewicz, Agnes I., et al.
Publicado: (2019)